Monograph Details
|
|
Central Nervous System
> Alzheimer's dementia
|
|
NAMENDA |
| Manufacturer |
|
Forest Laboratories |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
N-methyl-D-aspartate (NMDA) receptor antagonist. |
| Generic Name |
|
Memantine HCl 5mg, 10mg; tabs. |
| Also |
|
• NAMENDA ORAL SOLUTION
|
| Indications |
|
Moderate to severe dementia of the Alzheimer's type. |
| Children |
|
Not recommended. |
| Adults |
|
Initially 5mg once daily; titrate at intervals of at least 1 week to 5mg twice daily, then to 5mg and 10mg as separate doses, then to 10mg twice daily (prescribe Titration Pak for 1st 4 weeks). Severe renal impairment (CrCl 5–29mL/min): titrate to max 5mg twice daily. |
| Precautions |
|
Alkalinized urine (eg, renal tubular acidosis, severe UTI) increases memantine serum levels. Seizure disorder. Pregnancy (Cat.B). Nursing mothers. |
| Interactions |
|
Caution with other NMDA antagonists (eg, amantadine, ketamine, dextromethorphan, felbamate). May affect or be affected by renally-excreted drugs (eg, triamterene, HCTZ, cimetidine, nicotine, ranitidine, quinidine). Plasma levels may be increased by urinary alkalinizers. |
| Adverse Reactions |
|
Dizziness, headache, constipation, hypertension, pain, GI upset, somnolence, hallucination, dyspnea. |
| How Supplied |
Tabs—60
Titration Pak (28 x 5mg + 21 x 10mg)—1
Oral soln—360mL |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
